For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...

Pegsunercept seems to be safe and efficacious at an 800 µg/kg dose; however, further dose-finding studies are warranted, as higher dosages or more frequent dosing might improve response rates ...

For patients with active lupus nephritis, obinutuzumab, a humanized type II anti-CD20 monoclonal antibody plus standard ...

Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated bleeds The data showed that Mim8 was well ...